{"id":"tpf-ccrt","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This regimen works by inhibiting cell division and inducing apoptosis in cancer cells. Docetaxel and cisplatin interfere with microtubule function and DNA replication, respectively, while fluorouracil inhibits thymidylate synthase, leading to DNA damage and cell death.","oneSentence":"TPF+CCRT is a chemotherapy regimen that combines docetaxel, cisplatin, and fluorouracil to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:28.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic squamous cell carcinoma of the head and neck"},{"name":"Locally advanced or metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07469241","phase":"PHASE2","title":"Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-10","conditions":"Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT05527782","phase":"PHASE2","title":"Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Universitario Doctor Peset","startDate":"2019-05-01","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT04223024","phase":"PHASE2","title":"Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-01-31","conditions":"Nasopharyngeal Carcinoma","enrollment":246},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504},{"nctId":"NCT03306121","phase":"PHASE3","title":"TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2017-11-13","conditions":"Nasopharyngeal Carcinoma","enrollment":322},{"nctId":"NCT04414566","phase":"PHASE3","title":"Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":562},{"nctId":"NCT01312350","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-11","conditions":"Hypopharyngeal Cancer","enrollment":40},{"nctId":"NCT03604965","phase":"PHASE3","title":"GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-07-21","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":204},{"nctId":"NCT03574324","phase":"PHASE3","title":"TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-05-24","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":266},{"nctId":"NCT03503136","phase":"PHASE3","title":"Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06","conditions":"Nasopharyngeal Carcinoma","enrollment":632}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Experimental group","Control group","TPF induction chemotherapy"],"phase":"phase_3","status":"active","brandName":"TPF+CCRT","genericName":"TPF+CCRT","companyName":"Guiyang Medical University","companyId":"guiyang-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The TPF+CCRT (Docetaxel, Cisplatin, and Fluorouracil with Concurrent Chemoradiotherapy) regimen is being studied in clinical trials for various head and neck cancers, including Nasopharyngeal Carcinoma, Locally Advanced Nasopharyngeal Carcinoma, and Locally Advanced Head and Neck Squamous Cell Carcinoma. This regimen typically involves Cisplatin-based induction chemotherapy, followed by a full course of PD-1/PD-L1 blockades and Reduced-dose IMRT (Intensity-Modulated Radiation Therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}